Prognostic values of preoperative NLR and PLR in patients with laryngeal squamous cell carcinoma

Laryngeal squamous cell carcinoma (LSCC) is a common head and neck cancer that remains as a major reason of morbidity and mortality. Estimates of 26,400 new cases of laryngeal cancer and 14,500 laryngeal cancer-related deaths in each year in China were reported (1), and the estimates of 13,430 and 3,620, respectively, in the United States (2). Treatment choices for LSCC include operation, radiotherapy, and chemotherapy either used alone or in combination (3-7). In spite of the progresses in diagnostic and treatment methods, the clinical prognosis of LSCC has not been significantly improved in the past 30 years. Finding effective biomarkers to identify patients who are prone to relapse or metastases and administering personalized therapy may improve the clinical outcomes